Wed, Apr 23, 2014, 5:13 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

POSCO Message Board

Alex1444 261 posts  |  Last Activity: Apr 21, 2014 9:32 PM Member since: May 27, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Market still missing the big picture on CUR

    by alex1444 Apr 16, 2014 1:09 PM
    alex1444 alex1444 Apr 21, 2014 9:32 PM Flag

    Maybe they're starting to get it now. Still expecting to see a high of $5-8/share this quarter.

    Sentiment: Strong Buy

  • Reply to

    ______Dr. Johe Speaks______

    by stem_cur Apr 16, 2014 9:32 PM
    alex1444 alex1444 Apr 17, 2014 4:51 PM Flag

    Electrical stimulation, possibly combined with stemcell therapy, could hold a lot of promise. Nerves obviously carry electrical pulses and can stimulate responses in dead frogs, etc. The whole idea of tissue re-animation in the Frankenstein story was that electricity is what would be the final part of making it work. Of course, that was just fiction, but I recall Jay Leno making a joke last year about an Israeli company that thought they could treat impotence (presumably from nerve damage) via electrical impulse. I don't know about that, but nerve regeneration and reconnection has been one of the "holy grails" of medicine for some time, and if they ever get it right it wouldn't surprise me if a combination of stemcell and electricity were involved.

    Sentiment: Strong Buy

  • Reply to

    does coeur make final bottom at $8.35

    by brolgaboy Apr 15, 2014 2:30 PM
    alex1444 alex1444 Apr 16, 2014 4:17 PM Flag

    Thanks Brolgaboy. What makes CDE especially annoying is that it's not even recognizing the silver price, no matter how anemic a rally there may be. I look at SLV as a proxy for silver, because the market open and close times are the same as CDE. Today SLV moved up slightly - it was $18.91 x $18.92 at the close (despite a bogus late post of $18.88). So SLV was up about 0.2% but CDE was still down 1.73%! And that on a good overall day for the market and dovish comments by Yellen.

    The low (for the past several years) for SLV was actually set on June 27 of last year, at $17.75. CDE traded that day around $12/share. Now SLV is about 6.5% above that low, yet CDE is down about 29% from where SLV set that low. If CDE matched SLV's gains from the low, it would be trading at about $12.78/share right now. If you give the share price a modest 2x leverage vs. SLV, then CDE would be trading around $13.56, or nearly 60% higher than where it is now. I realize that SLV has its own production issues and does not trade at a particular ratio vs. silver, but this is getting beyond ridiculous. Very strange that SLV hit bottom over 9 months ago, but CDE hit a new 5 year low just yesterday.

    Sentiment: Strong Buy

  • alex1444 alex1444 Apr 16, 2014 3:01 PM Flag

    I did that long ago, when he was "Here2stay4everr" (or something like that). He's got so many names, keeps creating new ones, sometimes he even fakes a conversation with himself. But it's always the same old, same old when it comes to posts. He loves STEM, hates CUR, has seen STEM decline for years while CUR has risen and gone to new highs this year. He seems to have dedicated his "life" to repeating the same posts over and over again here, which is partly funny but mostly sad.

    Sentiment: Strong Buy

  • Reply to

    does coeur make final bottom at $8.35

    by brolgaboy Apr 15, 2014 2:30 PM
    alex1444 alex1444 Apr 16, 2014 2:56 PM Flag

    So far today it's the bottom (set yesterday), but another down day for the stock. CDE is the most annoying stock I've owned in a while. Silver can't seem to manage a rally and CDE is performing much worse than silver.

    Sentiment: Strong Buy

  • Just in the past couple days:
    - a fourth successful ALS patient went public regarding CUR.
    - Dr. Feldman expressed interest in a Phase 3 ALS trial using CUR's NSI-566.
    - University of California San Diego approved spinal cord injury trials for CUR.

    Additionally:
    - CUR's NSI-189 will have Phase 1B data soon.
    - Testing stroke treatment (NSI-566) in China
    - Testing spinal cord injury treatment (NSI-566) in South Korea.
    - Phase 2 ALS (NSI-566) trials underway in US
    - Agreement with NFL Alumni Association to perform Phase 2 NSI-189 testing on concussion/dementia-stricken former NFL players.
    - Possible partnerships in future.

    CUR has a decent valuation now, and thus can raise needed cash without extreme dilution. But the potential is also here for much higher valuation. There's never a sure thing, but this could be another AMGN or BIIB. Realize of course that those companies took many years to achieve massive share price increases. AMGN in the 1985-2000 period and BIIB 1995-2001 made especially strong gains for investors.

    Sentiment: Strong Buy

  • Reply to

    Triggered stops...

    by alpinemeadows2003 Apr 15, 2014 2:39 PM
    alex1444 alex1444 Apr 15, 2014 3:01 PM Flag

    That's a prime example of why using stop loss orders is stupid. Although when you recognize that others are using them, you can take advantage of that. It's insane that CUR dropped from above $4.60 to below $3.20 in just 4 trading days on no news. Congrats to whomever bought in the $3.20's or $3.30's today.

    Sentiment: Strong Buy

  • Reply to

    Oh boy, buy high, sell low, again:-)

    by mireksm Apr 15, 2014 12:45 PM
    alex1444 alex1444 Apr 15, 2014 12:55 PM Flag

    How's your STEM doing today? And how is STEM vs. CUR over the past year?

    Sentiment: Strong Buy

  • Reply to

    Back in @3.80, to $5 here we go!

    by canaries178 Apr 14, 2014 2:43 PM
    alex1444 alex1444 Apr 15, 2014 12:24 PM Flag

    Canaries, great move by you in selling some CUR shares on Wednesday afternoon, ahead of what turned out to be essentially a non-announcement by Dr. Feldman. I hope your new shares soon become profitable. What makes this especially painful is that there's actually a lot of good anecdotal news this month regarding some of CUR's ALS patients, and there should be more news coming soon. April was setting up to be a great month for CUR. That could still happen, but for now it's hard to stomach.

    Sentiment: Strong Buy

  • Reply to

    Wholesale dumping of all the small bios

    by market_ace Apr 15, 2014 12:00 PM
    alex1444 alex1444 Apr 15, 2014 12:08 PM Flag

    Yep, it's panic selling for no reason. That's usually the time to buy.

    Sentiment: Strong Buy

  • alex1444 alex1444 Apr 15, 2014 11:17 AM Flag

    What's with the "shell company" talk? Yes Dr. Johe owns a shell corporation and he works for CUR. He probably has it for tax purposes and/or to facilitate his divorce settlement. Shell corporations are not illegal. Only that multiple-name bozo tries to claim that somehow Dr. Johe's shell corporation means that what CUR is doing is not real. Ask Ted Harada and the others how fake this is. You are a mentally disturbed person to attack a company that is doing such good work for people with serious health problems.

    Sentiment: Strong Buy

  • Reply to

    CUR's upward trend, fundamentals are still intact

    by alex1444 Apr 12, 2014 11:47 AM
    alex1444 alex1444 Apr 15, 2014 11:02 AM Flag

    I hate to say it, but with today's dip to $3.60, the chart is officially broken, IMO. Doesn't mean it can't move up again, but that upward pattern appears to be over. Too bad there wasn't more news on Thursday. I'm still hanging on to my shares anyway, because there is too much potential good news on the horizon.

    Sentiment: Strong Buy

  • alex1444 alex1444 Apr 15, 2014 10:45 AM Flag

    Other posts by "freemarketer6" regarding CUR as an investment:

    August 20, 2012 11:46 am
    "In the universe of stocks right now there are few places worse than CUR to park money."
    Stock price: 51 cents/share

    March 20, 2013 11:57 am
    "So has Neuralcrap made any money for you clowns yet? Bwaaaaaaahahahaha"
    Stock price: $1.16/share

    October 31, 2013 9:44 am
    "I wouldn't touch CUR for any price! CUR is a story stock--nothing more."
    Stock price: $2.23/share

    January 6, 2014 10:28 am
    "CUR is a piece of garbage."
    Stock price: $3.22/share

    Wow, with a track record like that, you really have to listen when the guy talks about CUR. And do the opposite.

    Sentiment: Strong Buy

  • Reply to

    Breaking News: Robert A Bruno

    by teo_099 Apr 14, 2014 9:42 PM
    alex1444 alex1444 Apr 14, 2014 11:00 PM Flag

    No problem Teo, actually almost everybody calls all the various Nobel prizes "Nobel Peace Prizes", including myself, at one time or another. Just couldn't resist pointing that out. Actually I'm hoping to win a "Nobel Peace Prize in Economics" some day. It will be earned from a combination of discrediting both the Phillips Curve and the Efficient Market Hypothesis as useful tools in setting interest rate targets and managing investment portfolios, respectively. The prize is worth a million bucks or so, which would make me feel very peaceful. Seriously, I hope Mr. Bruno and the others continue to do well with their ALS treatments, which is a lot more important than me winning some darn prize.

    Sentiment: Strong Buy

  • Reply to

    New Trial Patient Blog -- Kreg Palko

    by biopeon Apr 14, 2014 4:10 PM
    alex1444 alex1444 Apr 14, 2014 10:29 PM Flag

    The September archive on the Palko website does mention that they hope to have Kreg accepted in the "Brainstorm" treatment at Massachusetts General. HOWEVER, that appears to be a mistake. Neuralstem (i.e. CUR) is at Mass General. The same Palko blog has an entry now (i.e. April 2014) which says:

    "The next Neuralstem transplant will take place on April 10 at Massachusetts General Hospital. Kreg completed some additional testing this week at the hospital and he passed with flying colors. He is currently the backup candidate for the April 10 date. ..."

    Sentiment: Strong Buy

  • Reply to

    Breaking News: Robert A Bruno

    by teo_099 Apr 14, 2014 9:42 PM
    alex1444 alex1444 Apr 14, 2014 10:05 PM Flag

    Maybe a Nobel prize in "physiology or medicine" would be in order. Probably not a peace prize. Although Richard Garr and Karl Johe would be more worthy of the Nobel peace prize than Barack Obama or Al Gore.

    Sentiment: Strong Buy

  • Reply to

    Pete

    by omeg4 Apr 14, 2014 5:59 PM
    alex1444 alex1444 Apr 14, 2014 6:23 PM Flag

    Pete did not buy and sell on news. He bought after CUR had run up to the $4's and Dr. Eva Feldman was expected to soon release interim Phase 2 ALS data. When Dr. Feldman did not release any data other than to say things were going fine in Phase 2, he sold. So he basically sold on the absence of news, not on news. There will be news very soon, the Phase 1B data on NSI-189. And eventually there will be real data on Phase 2 ALS, not just a "things are going fine" statement. Pete may be proud of himself for selling after the non-news, but he missed the entire run-up from the low $1's into the $4's.

    Sentiment: Strong Buy

  • Reply to

    NBS is up on an acquisition

    by alex1444 Apr 14, 2014 2:57 PM
    alex1444 alex1444 Apr 14, 2014 4:32 PM Flag

    JBK, I remember NBS's generic Chinese drug maker as well - they bought it, promoted how great it would make them, then eventually sold it for a loss - what a joke. NBS keeps buying these companies, hoping that their revenues will give them the cachet of a successful business. Meanwhile they keep losing money and have developed nothing of value. NBS's share price is down something like 99% from its all-time high (much like STEM), while CUR has made new all-time highs in just the past month. But today, investors bought into the NBS acquisition, and maybe that's a good sign that there's still some interest in biotech.

    Sentiment: Strong Buy

  • Reply to

    NBS is up on an acquisition

    by alex1444 Apr 14, 2014 2:57 PM
    alex1444 alex1444 Apr 14, 2014 4:24 PM Flag

    Tony, yes PCT may turn out well for NBS, but I'm tired of them hyping it and acting as if PCT validates NBS's work. The NBS hypesters kept saying "There are a lot of stemcell companies, but not many have revenue like NBS". Well yeah, they have a small amount of revenue from it, after paying $20 million for it, but anyone could have bought it - they may have overpaid. NBS used to own some sort of Chinese generic drug maker, they bought that to show what a big "up and coming" company they were, then they sold it for a big loss. It's not like NBS has some plan that they've been sticking to, like CUR.

    But what irks me about NBS is not the company itself, it's the hypesters who feel they have to promote NBS by denigrating CUR, much like that name-changing moron does who promotes STEM here. From late 2012 through early 2013, you'd look at the Yahoo Finance page and see "oh look, there's news on CUR". Only to find out it was just some Seeking Alpha hype-job for NBS, where they would say "Don't buy CUR, it's fully valued, buy NBS instead". And they'd say that about all the other stemcell companies as well. With unsupportable statements like "NBS is clearly the most undervalued stemcell company", as if there's some way to absolutely ascertain true value for development-stage stemcell companies. So NBS has some heart-treatment in the works, like a lot of other stemcell companies that are further ahead, big deal. And they bought PCT with their blood-cord-banking thing which gives them "revenue". Never mind that if that ever became a real market, the big boys like Quest would get into it.

    I agree that some promotion is necessary, but I don't like the way NBS has done it. Further, there used to be posters on Yahoo that would come to this board claiming that NBS was better than CUR, give me a break. It just gave me a bad feeling about NBS, though maybe they'll be ok in the long run. I do think NBS has little to justify their market cap now though.

  • Reply to

    NBS is up on an acquisition

    by alex1444 Apr 14, 2014 2:57 PM
    alex1444 alex1444 Apr 14, 2014 3:17 PM Flag

    Tony, I don't like the way NBS gets in and out of so many businesses via acquisition and disgorgement. I also don't like the way they pay services like RedChip $10,000/month to promote them, and further don't like the way they were hyped on Seeking Alpha a year ago. On Seeking Alpha a year or so ago, a whole bunch of posters kept telling everyone that NBS was "the clear leader" in stemcell, which was hogwash. They also said that NBS was clearly "the most undervalued" and called all other stemcell stocks fully valued or overvalued.

    I have to wonder how all those Seeking Alpha "names" came to that "conclusion" - especially with such similar comments, about a company that is known to self-promote. If you read SA's write-ups related to NBS from late 2012 through early 2013 you'd know what this was about. There was even an "interview" from Seeking Alpha uber-hyper Brian Nichols with NBS's CEO Robin, I think late in 2012. I looked into NBS and found nothing particularly worthy, seemed like another ASTM but with a higher valuation. Maybe I'm wrong but that's my take on it. Obviously CUR has been the much better stock over the past year, so I'm glad that this was my takeaway at that time.

    Sentiment: Strong Buy

PKX
72.17-0.81(-1.11%)Apr 23 4:02 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.